Purpose: To describe outcomes of 6 patients treated with plaque radiotherapy for medulloepithelioma.
M edulloepithelioma is a rare, nonhereditary, congenital intraocular tumor arising from the nonpigmented ciliary body epithelium. 1 It usually presents within the first decade of life, and is rarely diagnosed in adulthood. Important clinical signs include lens changes (notch, subluxation), visible fleshy mass, intratumoral cysts, and presence of retrolental cyclitic membrane. [1] [2] [3] Patients can develop secondary features such as neovascular glaucoma or retinal detachment. Such patients occasionally have undergone surgery for cataract, glaucoma, or retinal detachment while the tumor was clinically unsuspected. Extraocular tumor extension is rare, but when present, the risk for regional and distant metastases is increased. 1, [4] [5] [6] Treatment for medulloepithelioma has traditionally been observation or enucleation of the affected eye, but plaque radiotherapy is an option in selected cases for globe salvage and sight preservation. There have been few reports on plaque radiotherapy for medulloepithelioma. [7] [8] [9] [10] We report 6 cases of plaque radiotherapy for medulloepithelioma.
METHODS
Computerized medical records were reviewed to identify patients diagnosed with medulloepithelioma as confirmed by cytopathology, and treated with plaque radiotherapy in the Ocular Oncology Service at Wills Eye Hospital, Philadelphia, PA, United States from January 1970 to December 2017. Patients with a definitive histopathologic diagnosis of medulloepithelioma treated with plaque radiotherapy as primary or secondary treatment were included in the study. Patients managed with alternative modalities were excluded. This study was conducted in compliance with the Health Insurance Portability and Accountability Act. Ethical approval of the study was obtained from the Institutional Review Board of the Wills Eye Hospital. Because this retrospective study was carried out using patient data in an anonymous manner, the requirement for written informed consent from individual patients was waived.
Records were retrospectively reviewed for patient demographics and pertinent medical history, including age, race, sex, birth history, prior ocular surgery, history of ocular trauma, presence of pleuropulmonary blastoma, and genetic test results for DICER1 mutation. Presenting features were assessed, including ocular symptoms; best-corrected visual acuity; intraocular pressure; tumor laterality, location, configuration, color, largest basal diameter and thickness, distance to optic disc and foveola; ocular structures involved; presence of feeder vessels; presence of iris heterochromia, corectopia, ectropion, neovascularization, and synechiae; lens changes (coloboma, subluxation, cataract); presence of retrolental neoplastic cyclitic membrane, anterior Cytology results from fine-needle aspiration biopsy (FNAB) were recorded. The biopsy was performed with a 27-gauge needle, and cytopathology diagnosis was confirmed by a cytopathologist. Tumors were classified into 4 categories: benign nonteratoid, malignant nonteratoid, benign teratoid, and malignant teratoid. Nonteratoid type consisted purely of cells resembling ciliary epithelium (diktyoma), and teratoid type revealed heteroplastic elements (cartilage, rhabdomyoblasts, brain) in addition to proliferation of medullary neuroepithelium.
Treatment details for plaque radiotherapy included plaque as primary or secondary treatment, date of surgery, isotope used, plaque shape and size, and radiation dose at tumor apex and base. Outcomes measured at 3-, 6-, 12-, and 24-month followup included best-corrected visual acuity, tumor status (regression in tumor basal diameter and thickness, recurrence), presence or absence of associated features [corneal edema, synechiae, neovascularization of the iris (NVI), vitreous hemorrhage, retinal detachment, subretinal fluid], radiation complications (cataract, maculopathy, papillopathy, phthisis bulbi) and treatment (observation, bevacizumab injection, enucleation, cataract surgery, cryotherapy, glaucoma eyedrops), metastasis, and death.
RESULTS
This series comprises 6 cases of medulloepithelioma that were confirmed with FNAB and managed with plaque radiotherapy as primary (n = 5) or secondary (n = 1) treatment. Patient demographics, presenting symptoms, tumor characteristics, treatment and its outcomes are shown in Table 1 . The median patient age at diagnosis was 41 months (mean, 145; range, 10-624 months). Patient demographics included white race (n = 6) and female sex (n = 5). Patients presented with strabismus (n = 1), decreased vision (n = 1), ocular pain (n = 1), hyphema (n = 1), corectopia (n = 1), and visible iris lesion (n = 1). The mean tumor basal diameter was 11.2 mm (median, 10.0; range, 7.0-16.0 mm), and mean tumor thickness was 6.8 mm (median, 6.4; range, 3.1-11.0 mm). Related findings included cataract (n = 2), iris neovascularization (n = 5), secondary glaucoma (n = 2), and ectropion uveae (n = 2). The mean radiation dose to tumor apex was 44 Gy (median, 38; range, 35-70 Gy). At a mean follow-up of 59 months (range, 12-210 months), tumor control was achieved in 5 eyes (83%) with globe salvage in 4 eyes (67%). No patient had evidence of metastases or death at the last followup visit. Individual cases are described below.
Case 1
A 32-month-old white female developed a gray iris lesion (Fig. 1A) in the left eye (OS). Examination showed NVI and an iridociliary mass, measuring 14.0 mm in base and 6.0 mm in thickness. On UBM, intralesional cysts and intrinsic calcification were revealed (Fig. 1B) . Medulloepithelioma was confirmed by FNAB. Iodine-125 (I-125) plaque radiotherapy with tumor apex dose of 35 Gy was applied with tumor regression to 2.6 mm in thickness. At 25 months of follow-up, cataract extraction was performed. At 55 months of follow-up, the tumor remained regressed (Figs. 1C, D) with no metastases.
Case 2
A 10-month-old white female was referred for a ciliary body mass in the right eye (OD). Examination disclosed extensive NVI, ectropion uveae, iris heterochromia, and ciliary body mass with intralesional cysts (Figs. 1E, F) , measuring 10.0 mm in base and 3.1 mm in thickness by UBM. Benign nonteratoid medulloepithelioma was confirmed with FNAB. The patient was treated with I-125 plaque radiotherapy with tumor apex dose of 36 Gy, resulting in decreased NVI and tumor regression (Figs. 1G, H) to a height of 1.5 mm without metastatic disease at 27-month follow-up.
Case 3
A 19-month-old white male with congenital hydronephrosis and history of exotropia with dilated pupil OD was found to have an intraocular mass. Examination OD revealed poor fix and follow, leukocoria, NVI, posterior synechiae, and a large ciliary body mass, measuring 16.0 mm in diameter and 11.0 mm in thickness with intralesional cysts (Figs. 2A-C) . After cytopathologic confirmation of benign nonteratoid medulloepithelioma, the tumor was treated with I-125 plaque radiotherapy at tumor apex dose of 40 Gy and intravitreal bevacizumab. At 4-month follow-up, tumor thickness had decreased to 9.2 mm (Figs. 2D, E) but hypotony, retinal detachment, and persistent NVI were noted. The patient later developed phthisis bulbi with pain and flat anterior chamber and was managed with (Fig. 2F) enucleation. Cytopathology confirmed regressed medulloepithelioma with no active tumor. At 12 months of follow-up, there was no metastatic disease.
Case 4
An 11-year-old white female with Stickler syndrome and previous dislocated lens developed hyphema and increased intraocular pressure after ocular trauma. Examination revealed band keratopathy with sector cataract, subluxed lens, and NVI OD. Funduscopically, a ciliary body mass was noted, pushing the lens nasally. Ultrasonography revealed tumor thickness of 6.8 mm and intralesional cysts. Cytopathology confirmed malignant nonteratoid medulloepithelioma. The patient was treated with I-125 plaque radiotherapy at tumor apex dose of 70 Gy. Tumor regression to 2.4 mm in thickness was found and remained stable at 38 months of follow-up, with no metastases.
Case 5
A 50-month-old white female noted ocular pain OS and was referred for presumed retinoblastoma. Examination revealed iris ectropion, NVI, lens notch, and a ciliary body mass with intralesional cysts, measuring 5.0 mm in thickness. Intraocular pressure OS was 46 mm Hg, suggestive of secondary glaucoma. After cytopathologic confirmation of benign nonteratoid medulloepithelioma, the patient was treated with iridocyclectomy. After local recurrence, the patient was treated with Cobalt-60 plaque radiotherapy with tumor apex dose of 50 Gy. The tumor showed noncontiguous recurrence 9 months after plaque radiotherapy, and the eye was enucleated. There was no evidence of metastases after 17 years of follow-up. 
DISCUSSION
Medulloepithelioma is a rare congenital tumor, characteristically presenting as a ciliary body mass with intratumoral cysts, lens changes, leukocoria, and NVI. [1] [2] [3] 6 Management of medulloepithelioma has traditionally been observation or enucleation, with few cases suitable for local resection due to high risk of recurrence. 2, 4, 6 Recently, plaque radiotherapy has been described as globe salvage therapy for smaller, localized tumors. [7] [8] [9] [10] We reviewed 6 patients with medulloepithelioma managed with plaque radiotherapy as primary (n = 5, 83%) or secondary (n = 1, 17%) treatment. In this cohort, the medulloepithelioma was small to medium in size, with a mean diameter of 11.2 mm and mean thickness of 6.8 mm. Careful evaluation in each case confirmed a localized tumor without anterior chamber seeding or neoplastic membrane into the vitreous cavity. Compared with a large analysis of medulloepitheliomas in general, managed with multiple modalities, Kaliki et al 3 found the mean tumor base was 11.0 mm with thickness of 7.0 mm, tumor seeding in 2%, and neoplastic membrane in 51%. Our selected tumors were purely localized to the iridociliary region. Genetic testing for DICER1 was performed (n = 2) due to its association with pleuropulmonary blastoma,3 and both cases were negative for DICER1.
In this cohort, the mean radiation dose to tumor apex was 44 Gy (median, 38; range, 35-70 Gy). Tumor regression was documented in 83% (n = 5), and enucleation was necessary in 33% (n = 2). Of 5 tumors that regressed, the mean decrease in thickness was 42% from 7.1 mm at presentation to 4.1 mm after treatment. One tumor showed no regression. Tumor regression was evident with decreased tumor thickness on UBM and ultrasonography. Enucleation was necessary in 2 cases for large tumor (thickness 11.0 mm) with regression to 9.2 mm, but with phthisis bulbi. The second case had radiotherapy after resection, but further noncontiguous recurrence necessitated enucleation.
In all the 5 pediatric patients, NVI was present on diagnosis of medulloepithelioma, and 4 of them received adjuvant intravitreal bevacizumab (Avastin). The mean number of injections was 2 (median, 2; range, 1-4), with the first injection given within 1 week after plaque removal. After bevacizumab injection, NVI regression was noted in 2 patients (50%), but remained persistent NVI in the other 2 (50%). The adult patient had no NVI and received prophylactic bevacizumab after plaque removal.
Radiation adverse effects included cataract (n = 4), retinal neovascularization (n = 1), cystoid macular edema (n = 1), subretinal fluid (n = 1), retinal detachment (n = 1), and phthisis bulbi (n = 1). Of 4 salvaged eyes, 2 (50%) achieved visual acuity greater than 20/80. There was no evidence of metastasis or death in any case at the last follow-up visit. Our study confirms results reported by Poon et al, 10 who described tumor regression in 4 of 5 eyes with medulloepithelioma treated with plaque radiotherapy. Unlike our series, Poon et al 10 used Ruthenium-106, lacked cytopathologic confirmation, and treated smaller tumors (thickness <5 mm). The largest tumor successfully treated with plaque radiotherapy in previous reports was 7.6 mm in thickness using I-125 radiotherapy with radiation dose of 46 Gy at the tumor apex. 9 Our study demonstrated successful tumor control and globe salvage in medulloepithelioma for tumors up to nearly 9 mm in thickness. Of 6 tumors, 2 of 4 tumors with benign nonteratoid medulloepithelioma on cytopathology were enucleated. The other 2 patients had cytopathlogy revealing medulloepithelioma not otherwise specified or malignant nonteratoid medulloepithelioma; both tumors demonstrated regression without recurrence at the last follow-up visit. Although FNAB was used for confirmation of medulloepithelioma before conservative treatment with plaque radiotherapy, cytopathology did not seem to predict response to treatment in this small series. 11 However, a higher tumor apex dose of 70 Gy was applied to the patient with cytopathologically confirmed malignant nonteratoid medulloepithelioma. Final visual acuity in this patient was counting fingers secondary to cystoid macular edema, indicating that radiotherapy adverse effects can limit visual potential despite successful globe salvage. 
